These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 18069515)

  • 1. [Mechanisms of neuronal death in Huntington's disease. First part: general considerations and histopathological features].
    Bantubungi K; Blum D
    Rev Med Brux; 2007; 28(5):413-21. PubMed ID: 18069515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Mechanisms of neuronal death in Huntington's disease. Second part: therapeutic challenges].
    Bantubungi K; Blum D
    Rev Med Brux; 2007; 28(6):487-94. PubMed ID: 18265808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Huntington's disease: an update of therapeutic strategies.
    Kumar A; Kumar Singh S; Kumar V; Kumar D; Agarwal S; Rana MK
    Gene; 2015 Feb; 556(2):91-7. PubMed ID: 25447911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Huntington's disease: from molecular pathogenesis to clinical treatment.
    Ross CA; Tabrizi SJ
    Lancet Neurol; 2011 Jan; 10(1):83-98. PubMed ID: 21163446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Huntington's disease: clinical presentation and treatment.
    Novak MJ; Tabrizi SJ
    Int Rev Neurobiol; 2011; 98():297-323. PubMed ID: 21907093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Huntington's Disease: Mechanisms of Pathogenesis and Therapeutic Strategies.
    Jimenez-Sanchez M; Licitra F; Underwood BR; Rubinsztein DC
    Cold Spring Harb Perspect Med; 2017 Jul; 7(7):. PubMed ID: 27940602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant huntingtin can paradoxically protect neurons from death.
    Zuchner T; Brundin P
    Cell Death Differ; 2008 Mar; 15(3):435-42. PubMed ID: 17975550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Huntington's disease: clinical characteristics, pathogenesis and therapies.
    Nakamura K; Aminoff MJ
    Drugs Today (Barc); 2007 Feb; 43(2):97-116. PubMed ID: 17353947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies.
    Wang LH; Qin ZH
    Acta Pharmacol Sin; 2006 Oct; 27(10):1287-302. PubMed ID: 17007735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aging and neurodegeneration. Molecular mechanisms of neuronal loss in Huntington's disease.
    Lee ST; Kim M
    Mech Ageing Dev; 2006 May; 127(5):432-5. PubMed ID: 16527334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autopsy-proven Huntington's disease with 29 trinucleotide repeats.
    Kenney C; Powell S; Jankovic J
    Mov Disord; 2007 Jan; 22(1):127-30. PubMed ID: 17115386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene Therapy-Based Modeling of Neurodegenerative Disorders: Huntington's Disease.
    Young D
    Methods Mol Biol; 2016; 1382():383-95. PubMed ID: 26611601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Huntington's disease: how does huntingtin, an anti-apoptotic protein, become toxic?
    Rangone H; Humbert S; Saudou F
    Pathol Biol (Paris); 2004 Jul; 52(6):338-42. PubMed ID: 15261377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical and genetic features of Huntington disease.
    Sturrock A; Leavitt BR
    J Geriatr Psychiatry Neurol; 2010 Dec; 23(4):243-59. PubMed ID: 20923757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation.
    Charvin D; Vanhoutte P; Pagès C; Borrelli E; Caboche J
    Proc Natl Acad Sci U S A; 2005 Aug; 102(34):12218-23. PubMed ID: 16103364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential distribution of the normal and mutated forms of huntingtin in the human brain.
    Gourfinkel-An I; Cancel G; Trottier Y; Devys D; Tora L; Lutz Y; Imbert G; Saudou F; Stevanin G; Agid Y; Brice A; Mandel JL; Hirsch EC
    Ann Neurol; 1997 Nov; 42(5):712-9. PubMed ID: 9392570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length.
    Becher MW; Kotzuk JA; Sharp AH; Davies SW; Bates GP; Price DL; Ross CA
    Neurobiol Dis; 1998 Apr; 4(6):387-97. PubMed ID: 9666478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of normal huntingtin function: new developments in Huntington's disease research.
    Cattaneo E; Rigamonti D; Goffredo D; Zuccato C; Squitieri F; Sipione S
    Trends Neurosci; 2001 Mar; 24(3):182-8. PubMed ID: 11182459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Huntington's disease: new hope for therapeutics.
    McMurray CT
    Trends Neurosci; 2001 Nov; 24(11 Suppl):S32-8. PubMed ID: 11881743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Huntington's disease. Expanding horizons for treatment.
    McMurray CT
    Lancet; 2001 Dec; 358 Suppl():S37. PubMed ID: 11784586
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.